Vaccine formulations and uses thereof

Details Vaccine formulations and uses thereof Vaccine formulations and uses thereof

2011-08-16

2011-08-16

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Recombinant virus encoding one or more heterologous proteins...

C435S235100, C424S232100

Reexamination Certificate

active

07998488

ABSTRACT:
A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C. or in a liquid-frozen composition, for example between −10° C. and −30° C. or between −20° C. and −23.5° C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.

REFERENCES:
patent: 2879202 (1959-03-01), Stewart Aiston et al.
patent: 3577524 (1971-05-01), Pratt
patent: 4147772 (1979-04-01), McAleer et al.
patent: 4824668 (1989-04-01), Melchior et al.
patent: 5185146 (1993-02-01), Altenburger
patent: 5391491 (1995-02-01), Mundt et al.
patent: 6960345 (2005-11-01), Moyer
patent: 7256037 (2007-08-01), Ellenhorn et al.
patent: 2003/0215455 (2003-11-01), Reynolds et al.
patent: 2006/0008465 (2006-01-01), Steinaa et al.
patent: 7 773 (1970-03-01), None
patent: WO-91/09937 (1991-07-01), None
patent: WO-01/66137 (2001-09-01), None
patent: WO-2005/052116 (2005-06-01), None
Derwent accession No. 1971-45431S (1971).
GenBank accession No. AY603355, Vaccinia virus strain Acambis 3000 Modified Virus Ankara (MVA), complete genome, May 15, 2004.
Huang et al., “A time-efficient, linear-space local similarity algorithm”,Adv. Appl. Math., 12:337-57 (1991).
Maa et al., “Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation”,J. Pharm. Sci., 93:1912-23 (2004).
Reed et al., “A simple method of estimating fifty per cent endpoints”,Am. J. Hyg., 27:493-7 (1938).
Zang et al., “Immunogenicity of lyophilized MVA vaccine for HIV-1 in mice model”,Chem. Res. Chinese U., 23:329-32 (2007).
International Search Reporting and Written Opinion of the International Searching Authority, European Patent Office, PCT/US2009/064382, dated Feb. 1, 2010.

Affiliated with

Also associated with

Rating

Vaccine formulations and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine formulations and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine formulations and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2675640